Literature DB >> 17606479

Influence of intraoperative opioid on postoperative pain and pulmonary function after laparoscopic gastric banding: remifentanil TCI vs sufentanil TCI in morbid obesity.

L E C De Baerdemaeker1, S Jacobs, P Pattyn, E P Mortier, M M R F Struys.   

Abstract

BACKGROUND: Choice of opioid may influence postoperative pain, recovery, and respiratory homeostasis in morbid obesity. The aim of this study was to compare the effects of target-controlled infusions (TCIs) of remifentanil or sufentanil on postoperative analgesia, recovery, and pulmonary function after laparoscopic gastric banding.
METHODS: Forty morbidly obese patients undergoing laparoscopic gastric banding received BIS-guided desflurane anaesthesia combined with remifentanil TCI (Group R) or sufentanil TCI (Group S). Intraoperative haemodynamic stability, BIS controllability, and immediate recovery in the operating room were measured. Pulmonary function, modified Aldrete score, modified Observers Assessment of Alertness and Sedation score, blood gas analysis, and visual analogue score for pain and postoperative nausea and vomiting were measured on admission to the post-anaesthesia care unit and 30, 60, 120 min afterwards. After operation, patients received patient-controlled analgesia with morphine.
RESULTS: During the first two postoperative hours, cumulative morphine consumption was higher in the remifentanil group compared with the sufentanil group, but was equal values after that time. Recovery profiles and spirometry showed no significant differences. During maintenance, remifentanil gave a better haemodynamic stability.
CONCLUSIONS: As few differences occurred in the postoperative period, the theoretical advantage of remifentanil over the longer acting sufentanil can be questioned when using TCI technology.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17606479     DOI: 10.1093/bja/aem164

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  8 in total

1.  Comparison of propofol-remifentanil versus propofol-ketamine deep sedation for third molar surgery.

Authors:  Kyle J Kramer; Steven Ganzberg; Simon Prior; Robert G Rashid
Journal:  Anesth Prog       Date:  2012

2.  Anesthetic Pharmacology and the Morbidly Obese Patient.

Authors:  Jerry Ingrande; Hendrikus Jm Lemmens
Journal:  Curr Anesthesiol Rep       Date:  2012-12-13

Review 3.  Challenges in the optimisation of post-operative pain management with opioids in obese patients: a literature review.

Authors:  C Lloret-Linares; A Lopes; X Declèves; A Serrie; S Mouly; J-F Bergmann; S Perrot
Journal:  Obes Surg       Date:  2013-09       Impact factor: 4.129

4.  Gender-related difference in postoperative pain after laparoscopic Roux-En-Y gastric bypass in morbidly obese patients.

Authors:  Ahed Zeidan; Sultan Al-Temyatt; Hany Mowafi; Tharwat Ghattas
Journal:  Obes Surg       Date:  2013-11       Impact factor: 4.129

5.  Remifentanil, fentanyl, or the combination in surgical procedures in the United States: predictors of use in patients with organ impairment or obesity.

Authors:  David Alexander Sclar
Journal:  Clin Drug Investig       Date:  2015-01       Impact factor: 2.859

6.  Comparison of effects of intraoperative nefopam and ketamine infusion on managing postoperative pain after laparoscopic cholecystectomy administered remifentanil.

Authors:  Sung Kwan Choi; Myung Ha Yoon; Jung Il Choi; Woong Mo Kim; Bong Ha Heo; Keun Seok Park; Ji A Song
Journal:  Korean J Anesthesiol       Date:  2016-07-25

Review 7.  Remifentanil-induced postoperative hyperalgesia: current perspectives on mechanisms and therapeutic strategies.

Authors:  Cristina Santonocito; Alberto Noto; Claudia Crimi; Filippo Sanfilippo
Journal:  Local Reg Anesth       Date:  2018-04-09

Review 8.  Pain Therapy Guided by Purpose and Perspective in Light of the Opioid Epidemic.

Authors:  Amie L Severino; Arash Shadfar; Joshua K Hakimian; Oliver Crane; Ganeev Singh; Keith Heinzerling; Wendy M Walwyn
Journal:  Front Psychiatry       Date:  2018-04-23       Impact factor: 4.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.